Get the Stockscreener App
0.905
0.10%
0.0009
After Hours:
.91
0.005
+0.55%
Chimerix Inc stock is traded at $0.905, with a volume of 78,394.
It is up +0.10% in the last 24 hours and up +3.74% over the past month.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.
See More
Previous Close:
$0.9041
Open:
$0.9
24h Volume:
78,394
Relative Volume:
0.41
Market Cap:
$84.49M
Revenue:
$324.00K
Net Income/Loss:
$-82.10M
P/E Ratio:
0.4393
EPS:
2.06
Net Cash Flow:
$-69.18M
1W Performance:
+2.84%
1M Performance:
+3.74%
6M Performance:
-3.52%
1Y Performance:
-6.94%
1-Day Range:
$0.90
$0.9395
1-Week Range:
$0.87
$0.9426
52-Week Range:
$0.75
$1.30
Chimerix Inc Stock (CMRX) Company Profile
Name
Chimerix Inc
Sector
Industry
Phone
919.806.1074
Address
2505 MERIDIAN PARKWAY, SUITE 100, DURHAM, NC
Compare CMRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMRX
Chimerix Inc
|
0.905 | 84.49M | 324.00K | -82.10M | -69.18M | 2.06 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Chimerix Inc Stock (CMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-23-23 | Initiated | Robert W. Baird | Outperform |
| Sep-07-22 | Initiated | CapitalOne | Overweight |
| Apr-29-21 | Initiated | Maxim Group | Buy |
| Apr-23-21 | Resumed | Cowen | Outperform |
| Mar-31-21 | Initiated | Jefferies | Buy |
| Mar-31-21 | Initiated | Wedbush | Outperform |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Feb-02-18 | Initiated | H.C. Wainwright | Buy |
| Aug-09-16 | Reiterated | FBR Capital | Mkt Perform |
| Feb-23-16 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-23-16 | Reiterated | FBR Capital | Mkt Perform |
| Feb-23-16 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Feb-22-16 | Downgrade | Citigroup | Buy → Neutral |
| Dec-29-15 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-28-15 | Downgrade | FBR Capital | Outperform → Mkt Perform |
| Dec-28-15 | Reiterated | Piper Jaffray | Overweight |
| Dec-17-15 | Initiated | UBS | Buy |
| Oct-05-15 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-03-15 | Initiated | Citigroup | Buy |
| Aug-18-15 | Initiated | FBR Capital | Outperform |
| Aug-06-15 | Reiterated | Brean Capital | Buy |
| May-11-15 | Reiterated | Brean Capital | Buy |
| Mar-04-15 | Initiated | Barclays | Overweight |
| Feb-12-15 | Reiterated | Stifel | Buy |
| Dec-31-14 | Reiterated | Brean Capital | Buy |
| Jul-08-14 | Resumed | Brean Capital | Buy |
View All
Chimerix Inc Stock (CMRX) Latest News
CMRX (Chimerix) Debt-to-EBITDA : -0.01 (As of Sep. 2024) - GuruFocus.com
Chimerix (FRA:CXF) Change In Receivables : €-0.13 Mil (TTM As of Sep. 2024) - GuruFocus.com
Wedbush Reiterates Outperform Rating for Chimerix (NASDAQ:CMRX) - Defense World
Chimerix (NASDAQ:CMRX) Earns Outperform Rating from Wedbush - MarketBeat
Chimerix, Inc. (NASDAQ:CMRX) Short Interest Update - MarketBeat
Chimerix updates officer severance plan, extends term - Investing.com
Chimerix (NASDAQ:CMRX) Earns Buy Rating from HC Wainwright - MarketBeat
Chimerix (CMRX) Announces Updated Phase 2 Response Assessment of Dordaviprone - StreetInsider.com
Chimerix Cancer Drug Shows 28% Response Rate in Phase 2 Brain Tumor Trial | CMRX Stock News - StockTitan
Wedbush Reaffirms “Outperform” Rating for Chimerix (NASDAQ:CMRX) - Defense World
Chimerix, Inc. (NASDAQ:CMRX) Q3 2024 Earnings Call Transcript - Insider Monkey
Chimerix Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Chimerix (CMRX) Reports Q3 Loss, Lags Revenue Estimates - MSN
Earnings call: Chimerix reports progress and financials for Q3 2024 - Investing.com India
Chimerix Inc (CMRX) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid Financial Challenges - GuruFocus.com
Chimerix Inc (CMRX) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid Financial ... - Yahoo Finance
Chimerix: Q3 Earnings Snapshot - CT Insider
Chimerix Inc (CMRX) Quarterly 10-Q Report - Quartzy
Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational Update - The Manila Times
Chimerix Q3 Loss Narrows to $22.9M; Phase 3 Trial On Track with $152.4M Cash Reserve | CMRX Stock News - StockTitan
Chimerix Inc (CMRX) Q3 2024: Everything You Need to Know Ahead o - GuruFocus.com
Chimerix Inc (CMRX) Q3 2024: Everything You Need to Know Ahead of Earnings - Yahoo Finance
Chimerix (CMRX) Set to Announce Earnings on Thursday - MarketBeat
Chimerix (NASDAQ:CMRX) Share Price Passes Above 200-Day Moving AverageWhat's Next? - MarketBeat
CMRXChimerix, Inc. Latest Stock News & Market Updates - StockTitan
LiveOne Leads The Pack Of 3 US Penny Stocks - Simply Wall St
Chimerix (NASDAQ:CMRX) Stock Price Passes Below 200 Day Moving AverageHere's Why - MarketBeat
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Smallpox Treatment Market to Experience Holistic Expansion - openPR
Chimerix (NASDAQ:CMRX) Share Price Passes Above 200-Day Moving Average – What’s Next? - Defense World
Chimerix (NASDAQ:CMRX) Stock Passes Above Two Hundred Day Moving AverageHere's Why - MarketBeat
Chimerix, Inc. (NASDAQ:CMRX) Shares Sold by Armistice Capital LLC - Defense World
Glioma Market Size was valued ~USD 650 million in 2023 and - openPR
Copart, Inc. (NASDAQ:CPRT) Shares Sold by Xponance Inc. - Defense World
Investor’s Delight: Compass Inc (COMP) Closes Strong at 6.20, Up 0.16 - The Dwinnex
Copart, Inc. (NASDAQ:CPRT) Shares Acquired by Summit Trail Advisors LLC - Defense World
Pacer Advisors Inc. Has $6.38 Million Stock Position in Copart, Inc. (NASDAQ:CPRT) - Defense World
Intech Investment Management LLC Sells 115,103 Shares of C.H. Robinson Worldwide, Inc. (NASDAQ:CHRW) - MarketBeat
Providence Capital Advisors LLC Acquires Shares of 61,800 Microchip Technology Incorporated (NASDAQ:MCHP) - MarketBeat
C.H. Robinson Worldwide (NASDAQ:CHRW) Sets New 12-Month High at $105.70 - Defense World
What is COMP’s price-to-sales ratio telling us about the company’s value? - US Post News
Company’s Banking Stock: Dissecting a -38.92% Quarterly Revenue Decline Amid Growth - The InvestChronicle
Investors in cash trouble should check out Cross Country Healthcares, Inc. (CCRN) - SETE News
C.H. Robinson Worldwide Sees Unusually High Options Volume (NASDAQ:CHRW) - MarketBeat
CHRS stock touches 52-week low at $1.01 amid market challenges - Investing.com India
Balance Sheet Insights: Compass Therapeutics Inc (CMPX)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Analytical Overview: Coherus Biosciences Inc (CHRS)’s Ratios Tell a Financial Story - The Dwinnex
Davidson Kempner Capital Management LP Acquires Shares of 150,000 C.H. Robinson Worldwide, Inc. (NASDAQ:CHRW) - Defense World
Integral Health Asset Management LLC Buys Shares of 275,000 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
A stock that deserves closer examination: Coherus Biosciences Inc (CHRS) - US Post News
Mount Yale Investment Advisors LLC Sells 2,003 Shares of Copart, Inc. (NASDAQ:CPRT) - Defense World
Chimerix Inc Stock (CMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Chimerix Inc Stock (CMRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Andriole Michael T. | PRESIDENT AND CEO |
Aug 08 '24 |
Sale |
0.83 |
1,285 |
1,065 |
462,453 |
| Andriole Michael T. | PRESIDENT AND CEO |
Feb 14 '24 |
Sale |
1.04 |
1,744 |
1,809 |
447,021 |
| LaSpaluto Michelle | CHIEF FINANCIAL OFFICER |
Feb 14 '24 |
Sale |
1.04 |
1,940 |
2,023 |
110,999 |
| Jakeman David | VP OF FINANCE AND ACCOUNTING |
Feb 14 '24 |
Sale |
1.04 |
2,660 |
2,777 |
141,232 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):